List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1281127/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer. Nature, 1994, 368, 258-261.	27.8	2,001
2	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
3	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
4	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
5	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 2014, 514, 92-97.	27.8	548
6	Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532
7	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
8	The Clinical Phenotype of Lynch Syndrome Due to Germ-Line PMS2 Mutations. Gastroenterology, 2008, 135, 419-428.e1.	1.3	480
9	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	6.3	428
10	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut, 2017, 66, 464-472.	12.1	411
11	Cancer risk and survival in <i>path_MMR</i> carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67, 1306-1316.	12.1	410
12	Genetic mapping of a second locus predisposing to hereditary non–polyposis colon cancer. Nature Genetics, 1993, 5, 279-282.	21.4	408
13	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	21.4	377
14	Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	21.4	374
15	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 2020, 22, 15-25.	2.4	365
16	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
17	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
18	Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet, The, 2020, 395, 1855-1863.	13.7	220

#	Article	IF	CITATIONS
19	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	6.2	201
20	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nature Communications, 2020, 11, 597.	12.8	193
21	Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 2021, 596, 393-397.	27.8	183
22	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
23	Lynch Syndrome Caused by Germline <i>PMS2</i> Mutations: Delineating the Cancer Risk. Journal of Clinical Oncology, 2015, 33, 319-325.	1.6	177
24	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
25	Molecular basis of HNPCC: Mutations of MMR genes. Human Mutation, 1997, 10, 89-99.	2.5	166
26	<i>CHEK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer. Journal of Clinical Oncology, 2012, 30, 4308-4316.	1.6	162
27	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
28	Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for <i>CHEK2</i> *1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	1.6	152
29	Cancer Risks for <i>PMS2</i> -Associated Lynch Syndrome. Journal of Clinical Oncology, 2018, 36, 2961-2968.	1.6	147
30	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	6.3	129
31	Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis. Human Molecular Genetics, 2014, 23, 4729-4737.	2.9	128
32	Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut, 2017, 66, 1657-1664.	12.1	127
33	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
34	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. American Journal of Human Genetics, 2020, 107, 432-444.	6.2	124
35	A widely expressed transcription factor with multiple DNA sequence specificity,CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. Genes Chromosomes and Cancer, 1998, 22, 26-36.	2.8	121
36	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120

#	Article	IF	CITATIONS
37	Colorectal cancer with and without microsatellite instability involves different genes. , 1999, 26, 247-252.		118
38	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Medicine, 2016, 13, e1002105.	8.4	118
39	Cumulative Burden of Colorectal Cancer–Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12.	1.3	110
40	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Human Molecular Genetics, 2016, 25, 2256-2268.	2.9	106
41	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
42	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	6.3	99
43	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	6.2	98
44	Microsatellite Instability and hMLH1 and hMSH2 Expression Analysis in Familial and Sporadic Colorectal Cancer. Laboratory Investigation, 2001, 81, 535-541.	3.7	97
45	No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	3.2	94
46	ldentification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
47	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. Gastroenterology, 2020, 158, 1300-1312.e20.	1.3	90
48	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
49	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
50	Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics, 2016, 48, 667-674.	21.4	77
51	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
52	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Medicine, 2020, 18, 396.	5.5	76
53	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.9	75
54	Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer. , 2000, 27, 17-25.		74

#	Article	IF	CITATIONS
55	Fine scale mapping of the breast cancer 16q12 locus. Human Molecular Genetics, 2010, 19, 2507-2515.	2.9	68
56	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genetics in Medicine, 2017, 19, 599-603.	2.4	67
57	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1503-1510.	2.5	64
58	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocrine-Related Cancer, 2016, 23, 77-91.	3.1	62
59	Genetic overlap between endometriosis and endometrial cancer: evidence from crossâ€disease genetic correlation and GWAS metaâ€analyses. Cancer Medicine, 2018, 7, 1978-1987.	2.8	62
60	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	6.2	59
61	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
62	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	5.1	51
63	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744.	7.1	51
64	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
65	Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. Hereditary Cancer in Clinical Practice, 2017, 15, 18.	1.5	49
66	A human compound heterozygote for two MLH1 missense mutations. Nature Genetics, 1997, 17, 135-136.	21.4	47
67	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Human Molecular Genetics, 2014, 23, 5545-5557.	2.9	46
68	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	1.9	45
69	Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. Human Genetics, 2019, 138, 307-326.	3.8	44
70	Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 2021, 70, 1325-1334.	12.1	44
71	Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population. Oncology Reports, 2016, 36, 2823-2835.	2.6	43
72	Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Research, 2016, 18, 22.	5.0	43

#	Article	IF	CITATIONS
73	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. Breast Cancer Research, 2017, 19, 119.	5.0	43
74	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	3.5	39
75	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
76	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39
77	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37
78	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology, 2021, 160, 1164-1178.e6.	1.3	36
79	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports, 2015, 5, 17369.	3.3	35
80	Mendelian randomization analysis of C-reactive protein on colorectal cancer risk. International Journal of Epidemiology, 2019, 48, 767-780.	1.9	35
81	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	5.1	35
82	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 2016, 25, 3863-3876.	2.9	33
83	Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 3759-3770.	7.0	32
84	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 2016, 7, 80140-80163.	1.8	31
85	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
86	Exome sequencing in one family with gastric- and rectal cancer. BMC Genetics, 2016, 17, 41.	2.7	31
87	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
88	GermlineBRCA1 andHMLH1 mutations in a family with male and female breast carcinoma. , 2000, 85, 796-800.		29
89	Germline mutation screening of the STK11/LKB1 gene in familial breast cancer with LOH on 19p. Clinical Genetics, 2000, 57, 394-397.	2.0	28
90	Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses. BMC Medicine, 2020, 18, 229.	5.5	28

#	Article	IF	CITATIONS
91	Systematic meta-analyses, field synopsis and global assessment of the evidence of genetic association studies in colorectal cancer. Gut, 2020, 69, 1460-1471.	12.1	27
92	Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. American Journal of Clinical Nutrition, 2021, 113, 1490-1502.	4.7	27
93	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
94	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. European Journal of Human Genetics, 2017, 25, 432-438.	2.8	26
95	Mendelian Randomization of Circulating Polyunsaturated Fatty Acids and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 860-870.	2.5	26
96	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	2.5	26
97	Four separate regions on chromosome 17 show loss of heterozygosity in familial breast carcinomas. Human Genetics, 1993, 91, 6-12.	3.8	25
98	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocrine-Related Cancer, 2015, 22, 851-861.	3.1	25
99	Identification of Novel Loci and New Risk Variant in Known Loci for Colorectal Cancer Risk in East Asians. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 477-486.	2.5	25
100	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	2.5	24
101	Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Research, 2019, 21, 144.	5.0	24
102	BRCA1 Mutations in a Population-based Study of Breast Cancer in Stockholm County. Genetic Testing and Molecular Biomarkers, 2004, 8, 127-132.	1.7	21
103	Bioinformatics for Human Genetics: Promises and Challenges. Human Mutation, 2011, 32, 495-500.	2.5	21
104	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	1.8	21
105	Low frequency of hMSH2 mutations in Swedish HNPCC families. , 1997, 74, 134-137.		20
106	BRCA2 germline mutations in Swedish breast cancer families. European Journal of Human Genetics, 1998, 6, 134-139.	2.8	20
107	The gynecological surveillance of women with Lynch syndrome in Sweden. Gynecologic Oncology, 2015, 138, 717-722.	1.4	20
108	DGGE screening of mutations in mismatch repair genes (hMSH2 and hMLH1) in 34 Swedish families with colorectal cancer. Clinical Genetics, 1998, 53, 131-135.	2.0	19

#	Article	IF	CITATIONS
109	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 2016, 6, 32512.	3.3	19
110	The <i>BRCA2</i> c.68-7TÂ>ÂA variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	2.5	19
111	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	2.5	19
112	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	8.2	19
113	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
114	Exome sequencing in 51 early onset nonâ€familial CRC cases. Molecular Genetics & Genomic Medicine, 2019, 7, e605.	1.2	17
115	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051.	12.8	16
116	Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. British Journal of Cancer, 2018, 118, 1639-1647.	6.4	16
117	The effect of genotypes and parent of origin on cancer risk and age of cancer development in PMS2 mutation carriers. Genetics in Medicine, 2016, 18, 405-409.	2.4	15
118	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget, 2015, 6, 7390-7407.	1.8	15
119	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
120	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
121	Genetic anticipation in Swedish Lynch syndrome families. PLoS Genetics, 2017, 13, e1007012.	3.5	14
122	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Research and Treatment, 2020, 181, 423-434.	2.5	14
123	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget, 2017, 8, 18381-18398.	1.8	14
124	Hereditary breast cancer in sweden: a predominance of maternally inherited cases. Breast Cancer Research and Treatment, 1992, 24, 159-165.	2.5	12
125	Finnish mutations in Swedish HNPCC families. Nature Medicine, 1995, 1, 1104-1104.	30.7	12
126	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	2.5	12

#	Article	IF	CITATIONS
127	Familial breast cancer and genes involved in breast carcinogenesis. Breast Cancer Research and Treatment, 1995, 34, 171-183.	2.5	11
128	Mapping of a new MAP kinase activated protein kinase gene (3PK) to human chromosome band 3p21.2 and ordering of 3PK and two cosmid markers in the 3p22–p21 tumour-suppressor region by two-colour fluorescencein situ hybridization. Chromosome Research, 1996, 4, 310-313.	2.2	11
129	Hereditary Cancer. Acta Oncológica, 1999, 38, 439-447.	1.8	11
130	Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden. Hereditary Cancer in Clinical Practice, 2015, 13, 15.	1.5	11
131	A retrospective study of extracolonic, non-endometrial cancer in Swedish Lynch syndrome families. Hereditary Cancer in Clinical Practice, 2018, 16, 16.	1.5	11
132	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	2.4	11
133	Sublocalization of a locus at 3p21.3?23 predisposing to hereditary nonpolyposis colon cancer. Human Genetics, 1994, 94, 210-4.	3.8	10
134	Genome-wide scan of the effect of common nsSNPs on colorectal cancer survival outcome. British Journal of Cancer, 2018, 119, 988-993.	6.4	10
135	A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 564-575.	2.5	10
136	Recurrent, low-frequency coding variants contributing to colorectal cancer in the Swedish population. PLoS ONE, 2018, 13, e0193547.	2.5	10
137	Linkage Analysis in Familial Non-Lynch Syndrome Colorectal Cancer Families from Sweden. PLoS ONE, 2013, 8, e83936.	2.5	9
138	<i>PHIP</i> - a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 2017, 8, 102769-102782.	1.8	9
139	Defining New Colorectal Cancer Syndromes in a Population-based Cohort of the Disease. Anticancer Research, 2017, 37, 1831-1835.	1.1	9
140	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
141	The MLH1 c.1852_1853delinsGC (p.K618A) Variant in Colorectal Cancer: Genetic Association Study in 18,723 Individuals. PLoS ONE, 2014, 9, e95022.	2.5	7
142	Cancer risk susceptibility loci in a Swedish population. Oncotarget, 2017, 8, 110300-110310.	1.8	7
143	Colorectal cancer as a complex disease: defining at-risk subjects in the general population – a preventive strategy. Expert Review of Anticancer Therapy, 2004, 4, 377-385.	2.4	6
144	Familial cancer among consecutive uterine cancer patients in Sweden. Hereditary Cancer in Clinical Practice, 2014, 12, 14.	1.5	6

#	Article	IF	CITATIONS
145	Genetic analyses supporting colorectal, gastric, and prostate cancer syndromes. Genes Chromosomes and Cancer, 2019, 58, 775-782.	2.8	6
146	Response to Li and Hopper. American Journal of Human Genetics, 2021, 108, 527-529.	6.2	5
147	Variants of the PPARD Gene and Their Clinicopathological Significance in Colorectal Cancer. PLoS ONE, 2013, 8, e83952.	2.5	5
148	Predicting Outcome in Colonoscopic High-risk Surveillance. Anticancer Research, 2015, 35, 4813-9.	1.1	5
149	Testing strategies to reduce morbidity and mortality from Lynch syndrome. Scandinavian Journal of Gastroenterology, 2018, 53, 1535-1540.	1.5	4
150	Linkage analysis revealed risk loci on 6p21 and 18p11.2-q11.2 in familial colon and rectal cancer, respectively. European Journal of Human Genetics, 2019, 27, 1286-1295.	2.8	4
151	Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?. Cancers, 2021, 13, 2370.	3.7	4
152	Two novel colorectal cancer risk loci in the region on chromosome 9q22.32. Oncotarget, 2018, 9, 11170-11179.	1.8	4
153	Whole-genome Linkage Analysis and Sequence Analysis of Candidate Loci in Familial Breast Cancer. Anticancer Research, 2015, 35, 3155-65.	1.1	4
154	Enhanced detection of mutations in BRCA1 exon 11 using restriction endonuclease fingerprinting-single-strand conformation polymorphism. Journal of Molecular Medicine, 2000, 78, 580-587.	3.9	3
155	Screening for germline phosphatase and tensin homolog-mutations in suspected Cowden syndrome and Cowden syndrome-like families among uterine cancer patients. Oncology Letters, 2015, 9, 1782-1786.	1.8	3
156	Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation. Familial Cancer, 2018, 17, 531-537.	1.9	3
157	Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis. Human Genetics and Genomics Advances, 2020, 1, 100010.	1.7	3
158	Massive parallel sequencing in a family with rectal cancer. Hereditary Cancer in Clinical Practice, 2021, 19, 23.	1.5	3
159	A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. Scientific Reports, 2021, 11, 14763.	3.3	3
160	Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study. Nutrients, 2021, 13, 4164.	4.1	3
161	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
162	Sequencing for germline mutations in Swedish breast cancer families reveals novel breast cancer risk genes. Scientific Reports, 2021, 11, 14737.	3.3	2

#	Article	IF	CITATIONS
163	Molecular basis of HNPCC: Mutations of MMR genes. , 0, .		2
164	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	3.3	2
165	Colorectal cancer risk susceptibility loci in a Swedish population. Molecular Carcinogenesis, 2021, , .	2.7	2
166	A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. , 0, .		1
167	A Swedish Genome-Wide Haplotype Association Analysis Identifies a Novel Breast Cancer Susceptibility Locus in 8p21.2 and Characterizes Three Loci on Chromosomes 10, 11 and 16. Cancers, 2022, 14, 1206.	3.7	1
168	Increased risk for uterine cancer among first-degree relatives to Swedish gastric cancer patients. Hereditary Cancer in Clinical Practice, 2020, 18, 12.	1.5	0
169	Identification of known and novel familial cancer genes in Swedish colorectal cancer families. International Journal of Cancer, 2021, 149, 627-634.	5.1	0
170	Parent of Origin and Prognosis in Familial Breast Cancer in Sweden. Anticancer Research, 2017, 37, 1257-1262.	1.1	0